Eli Lilly and Company (LLY.US) Q3 2025 Earnings Conference Call
Live time: Oct 30, 2025 09:00
Eli Lilly and Company (LLY.US) Q3 2025 Earnings Conference Call
Live time: 10/30/2025 09:00:00
礼来公司 (LLY.US) 2025 年第三季度业绩电话会
Summary
00:03
Opening Remarks by Mike Zappar
Mike Zappar, Senior Vice President of Investor Relations, welcomes participants to Eli Lilly's Q3 2025 earnings call, introduces key executives, and provides legal disclaimers regarding forward-looking statements.
02:05
CEO Dave Ricks Q3 Business Overview
CEO Dave Ricks reports a strong Q3 for Eli Lilly with a 54% revenue increase year-over-year, driven by key products and global expansion. He highlights significant milestones, including FDA and EU approvals for new treatments.
04:49
CFO Lucas Matar's Financial Results
CFO Lucas Matar details Q3 financial performance, noting a 54% revenue growth and an 83.6% gross margin. He discusses increased R&D investments and updates on key product performances.
12:26
CSO Dan Skovronsky R&D Progress
CSO Dan Skovronsky highlights productive R&D activities, including positive trial results for orforgliperone and advancements in cardiovascular and metabolic health treatments.
27:48
Orforgliperone Market Path — Analyst: Terrence Flynn (Morgan Stanley)
CEO Dave Ricks discusses the strategy to expedite the launch of orforgliperone, emphasizing a comprehensive approach to meet global patient needs.
29:30
Monjaro International Expansion — Analyst: Chris Schott (J.P. Morgan)
Patrick Johnson explains Monjaro's strong international performance and future opportunities in new markets, highlighting the focus on patient activation for obesity treatment.
31:50
M&A and Market Dynamics — Analyst: Seamus Fernandez (Guggenheim)
CSO Dan Skovronsky addresses market dynamics and Lilly's strong R&D pipeline, emphasizing the company's leadership in obesity treatment innovation.
35:50
Pricing and Market Access — Analyst: James King (Deutsche Bank)
CEO Dave Ricks discusses the impact of Cigna's pricing model changes on market dynamics and the importance of clinical differentiation in drug positioning.
39:50
Orthofibon Market Potential — Analyst: Courtney Breen (AllianceBernstein)
Ken Caster outlines the market expansion potential for orforgliperone, emphasizing its benefits in glucose control and weight management.
46:41
Opagiferon Pricing Strategy — Analyst: Asad Haider (Goldman Sachs)
Elliot discusses the pricing and volume dynamics for opagiferon, highlighting the importance of consumer channels and international market learnings.
50:15
GLP-1 Pricing Impact — Analyst: Tim Anderson (BMO Capital Markets)
Ilya discusses the potential impact of IRA negotiated pricing on Lilly's GLP-1 products, emphasizing the differentiation of tirzepatide in value-based discussions.
54:35
GLP Pricing Expectations — Analyst: Umer Raffat (Evercore)
Lucas addresses the pricing dynamics for GLP-1 products, noting stable pricing trends and the importance of product differentiation in the market.
Related Notices
Recent Live Streams
Risk Disclaimer: The content on this page represents the author's personal opinions for general information purposes only and should not be used as a basis for any specific investment, business or commercial decision. It does not represent the position of Longbridge, and the platform makes no guarantees or commitments regarding the authenticity, accuracy or originality of the above content.